
Regenerative Medicine Market Report 2023-2033
Description
Regenerative Medicine Market Report 2023-2033
The Regenerative Medicine Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Growing number of Joint Ventures to fuel market growth
The demand for breakthrough techniques in tissue engineering, cell therapy, and stem cell use is increasing due to the rising prevalence of chronic diseases and clinical trials. Continuous joint ventures, mergers, acquisitions, and other strategic activity by various companies is helping the regenerative medicine market thrive. For instance, in October 2022, Dr. Vanessa Rodriguez Pares and Meso Numismatics, Inc. (MSSV), a biotech and numismatics-focused technology company, partnered with the new STEM LIFE clinic facility. This collaboration aims to promote regenerative medicine's high standards. Similar to this, Astellas Pharma Inc. and Pantherna Therapeutics GmbH entered into a technology evaluation agreement in October 2022 to carry out research to create mRNA-based regenerative medicine programmes employing direct reprogramming (trans-differentiation). Additionally, in October 2020, the world's largest pharmaceutical corporation Bayer bought Asklepios BioPharmaceutical, a gene therapy business with operations in San Sebastián, Spain, Edinburgh, and Paris, in a deal valued at up to US$ 4 billion. Such actions significantly influence the market for regenerative medicine's growth pace.
Product Recalls may hamper the market growth
Regenerative medicine is a speedily evolving field and involves the use of wide array of techniques to repair or replace damaged tissues and organs. With the increasing popularity and use of these products, there have been instances of product recalls in the regenerative medicine market. The growth of the regenerative medicine market can be impeded owing to the increasing number of product recalls. Biotech companies continue to face difficulties such as risk of product recalls and marketing their genetic medicine in the market. For instance, Bluebird Bio, a US-based gene therapy company, withdrew its gene therapy for a rare blood disorder from the German market in April 2021 after failing to reach an agreement on the treatment's cost with German health authorities. This recall impacted the company’s sales and brand image. Similarly, small-scale companies are severely affected as they fail to recover from losses due to product recalls because they operate without robust cash flow and brand recognition.
What Questions Should You Ask before Buying a Market Research Report?
Forecasts to 2033 and other analyses reveal commercial prospects
Segments Covered in the Report
By Product
The Regenerative Medicine Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Growing number of Joint Ventures to fuel market growth
The demand for breakthrough techniques in tissue engineering, cell therapy, and stem cell use is increasing due to the rising prevalence of chronic diseases and clinical trials. Continuous joint ventures, mergers, acquisitions, and other strategic activity by various companies is helping the regenerative medicine market thrive. For instance, in October 2022, Dr. Vanessa Rodriguez Pares and Meso Numismatics, Inc. (MSSV), a biotech and numismatics-focused technology company, partnered with the new STEM LIFE clinic facility. This collaboration aims to promote regenerative medicine's high standards. Similar to this, Astellas Pharma Inc. and Pantherna Therapeutics GmbH entered into a technology evaluation agreement in October 2022 to carry out research to create mRNA-based regenerative medicine programmes employing direct reprogramming (trans-differentiation). Additionally, in October 2020, the world's largest pharmaceutical corporation Bayer bought Asklepios BioPharmaceutical, a gene therapy business with operations in San Sebastián, Spain, Edinburgh, and Paris, in a deal valued at up to US$ 4 billion. Such actions significantly influence the market for regenerative medicine's growth pace.
Product Recalls may hamper the market growth
Regenerative medicine is a speedily evolving field and involves the use of wide array of techniques to repair or replace damaged tissues and organs. With the increasing popularity and use of these products, there have been instances of product recalls in the regenerative medicine market. The growth of the regenerative medicine market can be impeded owing to the increasing number of product recalls. Biotech companies continue to face difficulties such as risk of product recalls and marketing their genetic medicine in the market. For instance, Bluebird Bio, a US-based gene therapy company, withdrew its gene therapy for a rare blood disorder from the German market in April 2021 after failing to reach an agreement on the treatment's cost with German health authorities. This recall impacted the company’s sales and brand image. Similarly, small-scale companies are severely affected as they fail to recover from losses due to product recalls because they operate without robust cash flow and brand recognition.
What Questions Should You Ask before Buying a Market Research Report?
- How is the Regenerative Medicine Market evolving?
- What is driving and restraining the Regenerative Medicine Market?
- How will each Regenerative Medicine submarket grow over the forecast period and how much revenue will these submarkets account for in 2033?
- How will the market shares for each Regenerative Medicine submarket develop from 2023 to 2033?
- What will be the main driver for the overall market from 2023 to 2033?
- Will leading Regenerative Medicine Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
- Who are the leading players and what are their prospects over the forecast period?
- What are the Regenerative Medicine development projects for these leading companies?
- How will the industry evolve during the period between 2023 and 2033? What are the implications of Regenerative Medicine development projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the Regenerative Medicine Market?
- Where is the Regenerative Medicine Market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
- Our 232-page report provides 101 tables and 108 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them – NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2033 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising prices of regenerative medicines and recent developments.
Segments Covered in the Report
By Product
- Stem Cell Therapy
- Autologous
- Allogenic
- Tissue Engineering
- Scaffold
- Hydrogels
- Gene Therapy
- Others
- Regenerative Medicine
- Oncology
- Dermatology
- Musculoskeletal
- Neurology
- Cardiovascular
- Wound Healing
- Ophthalmology
- Others
- U.S.
- Canada
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Brazil
- Mexico
- Rest of Latin America Latin America
- GCC
- South Africa
- Rest of MEA
- Amgen
- Anterogen
- Avita Medical Inc.
- Bio Solutions. Co. Ltd
- Bluebird Bio Inc.
- Bristol Myers Squibb
- Gilead Sciences, Inc.
- Integra Life Sciences
- Misoblast Ltd
- Novartis AG
- Organogenesis Inc.
- Sarepta Therapeutics,Inc
- Sibino GeneTech Co. Ltd
- Smith & Nephew plc
- Terumo BCT
- Revenue forecasts to 2033 for Regenerative Medicine Market, 2023 to 2033 Market, with forecasts for Type of Product and Application at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2033 for five regional and 16 key national markets – See forecasts for the Regenerative Medicine Market, 2023 to 2033 market in North America, Europe, Asia-Pacific and Latin America and Middle East and Africa. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market – including company profiles of the major companies involved in the Regenerative Medicine Market, 2023 to 2033.
North America
Leading companies and the potential for market growth
How will the Regenerative Medicine Market, 2023 to 2033 report help you?
In summary, our 232-page report provides you with the following knowledge:
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Regenerative Medicine Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..
The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.
Table of Contents
232 Pages
- 1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Regenerative Medicine Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who is This Report for?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Reports
- 1.10 About
- 2 Executive Summary
- 3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 Increasing Strategic Activities and Collaborations
- 3.2.1.2 Rise in Research and Development Projects
- 3.2.1.3 Surging Government Support
- 3.2.2 Market Restraining Factors
- 3.2.2.1 Substantial Number of Product Recalls
- 3.2.2.2 Unapproved Products in the Market
- 3.2.3 Market Opportunities
- 3.2.3.1 Growing Research Partnership in Developed and Developing Countries across the globe
- 3.2.3.2 Growing awareness about the advances in medical research
- 3.2.3.3 Growing Investment and Funding
- 3.2.4 .COVID-19 Impact Analysis
- 3.3 Porter’s Five Forces Analysis
- 3.3.1 Bargaining Power of Suppliers
- 3.3.2 Bargaining Power of Buyers
- 3.3.3 Competitive Rivalry
- 3.3.4 Threat from Substitutes
- 3.3.5 Threat of New Entrants
- 3.4 PEST Analysis
- 4 Regenerative Medicine Market Analysis by Product
- 4.1 Key Findings
- 4.2 Product Segment: Market Attractiveness Index
- 4.3 Regenerative Medicine Market Size Estimation and Forecast by Product
- 4.4 Stem Cell Therapy
- 4.4.1 Regenerative Medicine Market Forecast by Stem Cell Therapy, 2023-2033 (US$ Bn)
- 4.4.1.1 Market Size by Region, 2023-2033 (US$ Bn)
- 4.4.1.2 Market Share by Region, 2023 & 2033 (%)
- 4.5 Tissue Engineering
- 4.5.1.1 Regenerative Medicine Market Forecast by Tissue Engineering, 2023-2033 (US$ Bn)
- 4.5.1.2 Market Size by Region, 2023-2033 (US$ Bn)
- 4.5.1.3 Market Share by Region, 2023 & 2033 (%)
- 4.6 Gene Therapy
- 4.6.1.1 Market Size by Region, 2023-2033 (US$ Bn)
- 4.6.1.2 Market Share by Region, 2023 & 2033 (%)
- 4.7 Others
- 4.7.1.1 Market Size by Region, 2023-2033 (US$ Bn)
- 4.7.1.2 Market Share by Region, 2023 & 2033 (%)
- 5 Regenerative Medicine Market Analysis by Application
- 5.1 Key Findings
- 5.2 Product Segment: Market Attractiveness Index
- 5.3 Regenerative Medicine Market Size Estimation and Forecast by Application
- 5.4 Oncology
- 5.4.1 Market Size by Region, 2023-2033 (US$ Bn)
- 5.4.2 Market Share by Region, 2023 & 2033 (%)
- 5.5 Dermatology
- 5.5.1 Market Size by Region, 2023-2033 (US$ Bn)
- 5.5.2 Market Share by Region, 2023 & 2033 (%)
- 5.6 Musculoskeletal
- 5.6.1 Market Size by Region, 2023-2033 (US$ Bn)
- 5.6.2 Market Share by Region, 2023 & 2033 (%)
- 5.7 Neurology
- 5.7.1 Market Size by Region, 2023-2033 (US$ Bn)
- 5.7.2 Market Share by Region, 2023 & 2033 (%)
- 5.8 Cardiovascular
- 5.8.1 Market Size by Region, 2023-2033 (US$ Bn)
- 5.8.2 Market Share by Region, 2023 & 2033 (%)
- 5.9 Wound Healing
- 5.9.1 Market Size by Region, 2023-2033 (US$ Bn)
- 5.9.2 Market Share by Region, 2023 & 2033 (%)
- 5.10 Ophthalmology
- 5.10.1 Market Size by Region, 2023-2033 (US$ Bn)
- 5.10.2 Market Share by Region, 2023 & 2033 (%)
- 5.11 Others
- 5.11.1 Market Size by Region, 2023-2033 (US$ Bn)
- 5.11.2 Market Share by Region, 2023 & 2033 (%)
- 6 Regenerative Medicine Market Analysis by Region
- 6.1 Key Findings
- 6.2 Regional Segment: Market Attractiveness Index
- 6.3 Regenerative Medicine Market Size Estimation and Forecast
- 7 North America Regenerative Medicine Market Analysis
- 7.1 Key Findings
- 7.2 North America Regenerative Medicine Market Attractiveness Index
- 7.3 North America Regenerative Medicine Market by Country, 2023, 2028 & 2033 (US$ Bn)
- 7.4 North America Regenerative Medicine Market Size Estimation and Forecast by Country
- 7.5 North America Regenerative Medicine Market Size Estimation and Forecast by Product
- 7.6 North America Regenerative Medicine Market Size Estimation and Forecast by Application
- 7.7 U.S. Regenerative Medicine Market Analysis
- 7.8 Canada Regenerative Medicine Market Analysis
- 8 Europe Regenerative Medicine Market Analysis
- 8.1 Key Findings
- 8.2 Europe Regenerative Medicine Market Attractiveness Index
- 8.3 Europe Regenerative Medicine Market by Country, 2023, 2028 & 2033 (US$ Bn)
- 8.4 Europe Regenerative Medicine Market Size Estimation and Forecast by Country
- 8.5 Europe Regenerative Medicine Market Size Estimation and Forecast by Product
- 8.6 Europe Regenerative Medicine Market Size Estimation and Forecast by Application
- 8.7 Germany Regenerative Medicine Market Analysis
- 8.8 France Regenerative Medicine Market Analysis
- 8.9 UK Regenerative Medicine Market Analysis
- 8.10 Italy Regenerative Medicine Market Analysis
- 8.11 Spain Regenerative Medicine Market Analysis
- 8.12 Russia Regenerative Medicine Market Analysis
- 8.13 Rest of Europe Regenerative Medicine Market Analysis
- 9 Asia Pacific Regenerative Medicine Market Analysis
- 9.1 Key Findings
- 9.2 Asia Pacific Regenerative Medicine Market Attractiveness Index
- 9.3 Asia Pacific Regenerative Medicine Market by Country, 2023, 2028 & 2033 (US$ Bn)
- 9.4 Asia Pacific Regenerative Medicine Market Size Estimation and Forecast by Country
- 9.5 Asia Pacific Regenerative Medicine Market Size Estimation and Forecast by Product
- 9.6 Asia Pacific Regenerative Medicine Market Size Estimation and Forecast by Application
- 9.7 Japan Regenerative Medicine Market Analysis
- 9.8 China Regenerative Medicine Market Analysis
- 9.9 India Regenerative Medicine Market Analysis
- 9.10 Australia Regenerative Medicine Market Analysis
- 9.11 South Korea Regenerative Medicine Market Analysis
- 9.12 Rest of Asia Pacific Regenerative Medicine Market Analysis
- 10 Latin America Regenerative Medicine Market Analysis
- 10.1 Key Findings
- 10.2 Latin America Regenerative Medicine Market Attractiveness Index
- 10.3 Latin America Regenerative Medicine Market by Country, 2023, 2028 & 2033 (US$ Bn)
- 10.4 Latin America Regenerative Medicine Market Size Estimation and Forecast by Country
- 10.5 Latin America Regenerative Medicine Market Size Estimation and Forecast by Product
- 10.6 Latin America Regenerative Medicine Market Size Estimation and Forecast by Application
- 10.7 Brazil Regenerative Medicine Market Analysis
- 10.8 Mexico Regenerative Medicine Market Analysis
- 10.9 Rest of Latin America Regenerative Medicine Market Analysis
- 11 MEA Regenerative Medicine Market Analysis
- 11.1 Key Findings
- 11.2 MEA Regenerative Medicine Market Attractiveness Index
- 11.3 MEA Regenerative Medicine Market by Country, 2023, 2028 & 2033 (US$ Bn)
- 11.4 MEA Regenerative Medicine Market Size Estimation and Forecast by Country
- 11.5 MEA Regenerative Medicine Market Size Estimation and Forecast by Product
- 11.6 MEA Regenerative Medicine Market Size Estimation and Forecast by Application
- 11.7 GCC Regenerative Medicine Market Analysis
- 11.8 South Africa Regenerative Medicine Market Analysis
- 11.9 Rest of MEA Regenerative Medicine Market Analysis
- 12 Company Profiles
- 12.1 Company share analysis, 2021
- 12.2 Amgen
- 12.2.1 Company Snapshot
- 12.2.2 Company Overview
- 12.2.3 Financial Analysis
- 12.2.3.1 Net Revenue, 2017-2021
- 12.2.3.2 R&D, 2017-2021
- 12.2.3.3 Regional Market Shares, 2021
- 12.2.4 Product Benchmarking
- 12.2.5 Strategic Outlook
- 12.3 Anterogen
- 12.3.1 Company Snapshot
- 12.3.2 Company Overview
- 12.3.3 Financial Analysis
- 12.3.3.1 Net Revenue, 2017-2021
- 12.3.3.2 R&D, 2017-2021
- 12.3.4 Product Benchmarking
- 12.4 Avita Medical, Inc.
- 12.4.1 Company Snapshot
- 12.4.2 Company Overview
- 12.4.3 Financial Analysis
- 12.4.3.1 Net Revenue, 2017-2021
- 12.4.3.2 R&D, 2017-2021
- 12.4.3.3 Regional Market Shares, 2021
- 12.4.4 Product Benchmarking
- 12.4.5 Strategic Outlook
- 12.5 Bio Solution Co. Ltd.
- 12.5.1 Company Snapshot
- 12.5.2 Company Overview
- 12.5.3 Financial Analysis
- 12.5.3.1 Net Revenue, 2017-2021
- 12.5.4 Product Benchmarking
- 12.5.5 Strategic Outlook
- 12.6 Bluebird Bio, Inc.
- 12.6.1 Company Snapshot
- 12.6.2 Company Overview
- 12.6.3 Financial Analysis
- 12.6.3.1 Net Revenue, 2017-2021
- 12.6.3.2 R&D, 2017-2021
- 12.6.4 Product Benchmarking
- 12.6.5 Strategic Outlook
- 12.7 Bristol Myers Squibb
- 12.7.1 Company Snapshot
- 12.7.2 Company Overview
- 12.7.3 Financial Analysis
- 12.7.3.1 Net Revenue, 2017-2022
- 12.7.3.2 R&D, 2017-2022
- 12.7.3.3 Regional Market Shares, 2022
- 12.7.4 Product Benchmarking
- 12.7.5 Strategic Outlook
- 12.8 Gilead Sciences, Inc.
- 12.8.1 Company Snapshot
- 12.8.2 Company Overview
- 12.8.3 Financial Analysis
- 12.8.3.1 Net Revenue, 2017-2022
- 12.8.3.2 R&D, 2017-2021
- 12.8.3.3 Regional Market Shares, 2022
- 12.8.4 Product Benchmarking
- 12.8.5 Strategic Outlook
- 12.9 Integra LifeSciences
- 12.9.1 Company Snapshot
- 12.9.2 Company Overview
- 12.9.3 Financial Analysis
- 12.9.3.1 Net Revenue, 2017-2021
- 12.9.3.2 R&D, 2017-2021
- 12.9.3.3 Regional Market Shares, 2021
- 12.9.4 Product Benchmarking
- 12.9.5 Strategic Outlook
- 12.10 Mesoblast Ltd
- 12.10.1 Company Snapshot
- 12.10.2 Company Overview
- 12.10.3 Financial Analysis
- 12.10.3.1 Net Revenue, 2017-2022
- 12.10.3.2 R&D, 2017-2021
- 12.10.4 Product Benchmarking
- 12.10.5 Strategic Outlook
- 12.11 Novartis AG
- 12.11.1 Company Snapshot
- 12.11.2 Company Overview
- 12.11.3 Financial Analysis
- 12.11.3.1 Net Revenue, 2017-2022
- 12.11.3.2 R&D, 2017-2022
- 12.11.3.3 Regional Market Shares, 2022
- 12.11.4 Product Benchmarking
- 12.11.5 Strategic Outlook
- 12.12 Organogenesis Inc.
- 12.12.1 Company Snapshot
- 12.12.2 Company Overview
- 12.12.3 Financial Analysis
- 12.12.3.1 Net Revenue, 2017-2021
- 12.12.3.2 R&D, 2017-2021
- 12.12.4 Product Benchmarking
- 12.12.5 Strategic Outlook
- 12.13 Sarepta Therapeutics, Inc.
- 12.13.1 Company Snapshot
- 12.13.2 Company Overview
- 12.13.3 Financial Analysis
- 12.13.3.1 Net Revenue, 2017-2021
- 12.13.3.2 R&D, 2017-2021
- 12.13.4 Product Benchmarking
- 12.13.5 Strategic Outlook
- 12.14 Sibiono GeneTech Co. Ltd
- 12.14.1 Company Snapshot
- 12.14.2 Company Overview
- 12.14.3 Product Benchmarking
- 12.15 Smith & Nephew plc
- 12.15.1 Company Snapshot
- 12.15.2 Company Overview
- 12.15.3 Financial Analysis
- 12.15.3.1 Net Revenue, 2017-2021
- 12.15.3.2 R&D, 2017-2021
- 12.15.3.3 Regional Market Shares, 2021
- 12.15.4 Product Benchmarking
- 12.15.5 Strategic Outlook
- 12.16 Terumo BCT
- 12.16.1 Company Snapshot
- 12.16.2 Company Overview
- 12.16.3 Financial Analysis
- 12.16.3.1 Net Revenue, 2017-2021
- 12.16.3.2 R&D, 2017-2021
- 12.16.3.3 Regional Market Shares, 2021
- 12.16.4 Product Benchmarking
- 12.16.5 Strategic Outlook
- 13 Conclusion and Recommendations
- 13.1 Concluding Remarks from
- 13.2 Recommendations for Market Players
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.